Showing 3921-3930 of 6982 results for "".
- Enrollment Complete for Journey’s Phase 3 Trials of DFD-29 in Papulopustular Rosaceahttps://practicaldermatology.com/news/enrollment-complete-for-journeys-in-phase-3-trials-of-dfd-29-in-papulopustular-rosacea/2461492/Journey Medical Corporation’s Phase 3 clinical trial program of DFD-29 for papulopustular rosacea is now fully enrolled. The Phase 3 clinical trials are part of a collaboration with Dr. Reddy’s Laboratories Ltd. for the ongoing development and commercialization of the D
- Crown Taps Shellie Hammock as EVP and General Counselhttps://practicaldermatology.com/news/crown-taps-shellie-hammock-as-evp-and-general-counsel/2461483/Shellie Hammock is Crown Laboratory’s new Executive Vice President and General Counsel and will hold a position on the Executive Leadership Team and Global Strategic Planning Team. This is a new position within Crown that will provide strategic legal oversight across al
- UCSF Apologizes for Dermatology Experiments in Prisoners in 1960shttps://practicaldermatology.com/news/ucsf-apologizes-for-dermatology-experiments-in-prisoners-in-1960s/2461477/The University of California, San Francisco apologized for conducting unethical dermatology experiments on at least 2,600 incarcerated men in the 1960s and 1970s. Experiments included putting pesticides and herbicides on the men’s skin and injecting it into the
- Practical Dermatology® Magazine’s Sister Publication Named Exclusive Media Partner for Octane’s Aesthetics Tech Forum 2023https://practicaldermatology.com/news/practical-dermatology-magazines-sister-publication-named-exclusive-media-partner-for-octanes-aesthetics-tech-forum-2023/2461474/Practical Dermatology’s sister publication, Modern Aesthetics® magazine, is the exclusive media partner for Octane’s Aesthetics Tech Forum 2023.Now in its fourth year, Octane's Aesthetics Tech Forum is a two-day immersive, in-person and digital
- First Participant Randomized in Dermaliq Therapeutic's Phase 1b/2 Trial Evaluating DLQ01 for AAhttps://practicaldermatology.com/news/first-participant-randomized-in-dermaliq-therapeutics-phase-1b2-trial-evaluating-dlq01-for-aa/2461470/The first participant has been randomized in a Phase 1b/2a trial of Dermaliq Therapeutics Inc.’s DLQ01 solution in men with androgenic alopecia. The trial is designed to evaluate the safety, systemic absorption, pharmacodynamics, and clinical efficacy of DLQ01 in men with and
- Endo Removes Qwo from Market Due to Concerns About Injection Site Bruising, Skin Discolorationhttps://practicaldermatology.com/news/endo-removes-qwo-from-market-due-to-concerns-about-injection-site-bruising-skin-discoloration/2461467/Endo International plc is ceasing the production and sale of Endo Aesthetics' Qwo (collagenase clostridium histolyticum-aaes) in light of market concerns about the extent and variability of bruising following initial treatment as well as the potential for prolonged skin discoloratio
- Arcutis Enrolls First Patient in Phase 1b Alopecia Areata Study of ARQ-255https://practicaldermatology.com/news/arcutis-enrolls-first-patient-in-phase-1b-alopecia-areata-study-of-arq-255/2461458/The first subject has been enrolled in a Phase 1b study evaluating Arcutis’ ARQ-255, a topical suspension of ivarmactinib, a potent and specific janus kinase 1 (JAK1) inhibitor, for the treatment of alopecia areata. ARQ-255 has been specifically formulated with Arcutis’
- Celebrities Come Together for EB Research Partnershiphttps://practicaldermatology.com/news/celebrities-come-together-for-eb-research-partnership/2461453/EB Research Partnership
- Study: Eating Grapes May Protect Skin from UV Damagehttps://practicaldermatology.com/news/study-eating-grapes-may-protect-skin-from-uv-damage/2461452/Consuming grapes can protect against ultraviolet (UV) damage to the skin, according to a new study in Antioxidants. Folks showed increased resistance to sunburn after consuming 2 ¼ cups of grapes every day
- Meta-analysis: Early Use of Emollients Can Help Preventing AD in High-risk Infantshttps://practicaldermatology.com/news/meta-analysis-early-use-of-emollients-can-help-preventing-ad-in-high-risk-infants/2461445/Early application of emollients is an effective strategy for preventing atopic dermatitis (AD) in high-risk infants, according to a meta-analysis in the Journal of the European Academy of Dermatology &am